CFP
HOME HELP CONTACT US FEEDBACK SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES SEARCH
QUICK SEARCH:   [advanced]


     

Can Fam Physician
Vol. 53, No. 2, February 2007, pp.229 - 230
Copyright © 2007 by The College of Family Physicians of Canada
This Article
Right arrow Résumé
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garcia-Bournissen, F.
Right arrow Articles by Koren, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garcia-Bournissen, F.
Right arrow Articles by Koren, G.

Motherisk Update

Exposure to sibutramine during pregnancy

Facundo Garcia-Bournissen, MD, Alon Shrim, MD and Gideon Koren, MD FRCPC
QUESTION One of my patients who was taking sibutramine to lose weight found out that she had unexpectedly conceived. The medication was stopped as soon as she found out, about 5 weeks into the pregnancy. Is the baby at risk? Should the pregnancy be aborted?

ANSWER No data to date suggest that involuntary exposure to sibutramine during pregnancy carries major risk of congenital malformations. Nevertheless, this medicationshould be avoided whenever possible during pregnancy, as there is little information on its effects.






HOME HELP CONTACT US FEEDBACK SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES SEARCH
Copyright © 2007 by The College of Family Physicians of Canada.